Saturday, 15 August 2020

Viralytics receives $1.4 mn R&D tax concession

24 April 2012 | News | By BioSpectrum Bureau

Singapore: Viralytics has received $1.467 million from the Australian Taxation Office for a research and development tax concession relating to the financial year to June 2012.

This is greater than the $871,000 originally estimated and published in the company's 2012 annual report.

These funds will contribute to Viralytics' oncolytic virus programs including the Phase 2 melanoma study in the US, and other potential indications including bladder cancer.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls